Buprenorphine-Naloxone (Buprenorphine HCl/Naloxone HCl) — Medicare Part D spending
Multiple manufacturers (15) · Rank #201 by total Part D spend · CMS data year 2023
Medicare Part D spent $231,087,289 on Buprenorphine-Naloxone (Buprenorphine HCl/Naloxone HCl) in 2023, the #201 drug by total Part D spending out of 3,598 drugs. That worked out to about $3.42 per dosage unit, $153 per claim and $1,557 per beneficiary, across 1,510,118 claims for 148,389 beneficiaries. Average spending per dosage unit fell -11.9% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Buprenorphine-Naloxone (Buprenorphine HCl/Naloxone HCl) spending at a glance (2023)
| Metric | Buprenorphine-Naloxone (Buprenorphine HCl/Naloxone HCl) |
|---|---|
| Total Part D spending (2023) | $231,087,289 |
| Total spending (2022) | $236,733,164 |
| Year-over-year change in total spending | -2.4% |
| Average spending per dosage unit (2023) | $3.42 |
| Change in spend per dosage unit (YoY) | -11.9% |
| Avg annual change per dosage unit (2019-2023 CAGR) | -5.9% |
| Average spending per claim (2023) | $153 |
| Average spending per beneficiary (2023) | $1,557 |
| Total claims (2023) | 1,510,118 |
| Beneficiaries (2023) | 148,389 |
| Total dosage units (2023) | 68,488,687 |
| Manufacturer(s) | Multiple manufacturers (15) |
| National rank by total spend (of 3,598 drugs) | #201 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $236,733,164 | $231,087,289 | -2.4% |
| Avg spend per dosage unit | $3.88 | $3.42 | -11.9% |
| Avg spend per claim | $166 | $153 | — |
| Avg spend per beneficiary | $1,760 | $1,557 | — |
| Total claims | 1,427,233 | 1,510,118 | — |
| Beneficiaries | 134,476 | 148,389 | — |
How Buprenorphine-Naloxone compares with nearby drugs
Drugs with total Part D spending closest to Buprenorphine-Naloxone (Buprenorphine HCl/Naloxone HCl):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Buprenorphine-Naloxone (Buprenorphine HCl/Naloxone HCl) (this drug, #201) | $231,087,289 | $3.42 | -11.9% |
| Lurasidone HCl (#199) | $232,956,481 | $12.06 | — |
| Combigan (Brimonidine Tartrate/Timolol) (#200) | $232,102,953 | $43.40 | +2.8% |
| Emgality Pen (Galcanezumab-Gnlm) (#202) | $229,252,597 | $716.06 | +3.1% |
| Icosapent Ethyl (#203) | $228,873,224 | $2.04 | -4.3% |
| Korlym (Mifepristone) (#204) | $228,814,734 | $632.17 | +9.0% |
Frequently asked questions
How much does Medicare Part D spend on Buprenorphine-Naloxone?
Medicare Part D spent $231,087,289 on Buprenorphine-Naloxone (Buprenorphine HCl/Naloxone HCl) in 2023 (the latest CMS data year), across 1,510,118 claims for 148,389 beneficiaries. That ranks #201 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Buprenorphine-Naloxone?
In 2023, the weighted average Medicare Part D spending per dosage unit for Buprenorphine-Naloxone (Buprenorphine HCl/Naloxone HCl) was $3.42. Compared with 2022 it fell -11.9%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Buprenorphine-Naloxone?
CMS attributes Buprenorphine-Naloxone (Buprenorphine HCl/Naloxone HCl) to Multiple manufacturers (15) in the 2023 Part D spending file. Average spending per claim was $153 and per beneficiary $1,557.
Is the Buprenorphine-Naloxone figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20